metyrapone has been researched along with Astrocytosis in 2 studies
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The status epilepticus (SE) induced by lithium-pilocarpine is a well characterized rodent model of the human temporal lobe epilepsy (TLE) which is accompanied by severe brain damage." | 7.85 | Metyrapone prevents brain damage induced by status epilepticus in the rat lithium-pilocarpine model. ( Bankstahl, JP; Bascuñana, P; Delgado, M; Fernández de la Rosa, R; García-García, L; Gomez, F; Pozo, MA; Shiha, AA; Silván, Á, 2017) |
| "Metyrapone (200 mg/kg) was administered either 30 min before or 1, 12 and 24 h after MCA occlusion." | 5.30 | Infarct volume and functional outcome after pre- and postoperative administration of metyrapone, a steroid synthesis inhibitor, in focal brain ischemia in the rat. ( Johansson, BB; Nordborg, C; Risedal, A, 1999) |
| "The status epilepticus (SE) induced by lithium-pilocarpine is a well characterized rodent model of the human temporal lobe epilepsy (TLE) which is accompanied by severe brain damage." | 3.85 | Metyrapone prevents brain damage induced by status epilepticus in the rat lithium-pilocarpine model. ( Bankstahl, JP; Bascuñana, P; Delgado, M; Fernández de la Rosa, R; García-García, L; Gomez, F; Pozo, MA; Shiha, AA; Silván, Á, 2017) |
| "Metyrapone (200 mg/kg) was administered either 30 min before or 1, 12 and 24 h after MCA occlusion." | 1.30 | Infarct volume and functional outcome after pre- and postoperative administration of metyrapone, a steroid synthesis inhibitor, in focal brain ischemia in the rat. ( Johansson, BB; Nordborg, C; Risedal, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-García, L | 1 |
| Shiha, AA | 1 |
| Fernández de la Rosa, R | 1 |
| Delgado, M | 1 |
| Silván, Á | 1 |
| Bascuñana, P | 1 |
| Bankstahl, JP | 1 |
| Gomez, F | 1 |
| Pozo, MA | 1 |
| Risedal, A | 1 |
| Nordborg, C | 1 |
| Johansson, BB | 1 |
2 other studies available for metyrapone and Astrocytosis
| Article | Year |
|---|---|
Metyrapone prevents brain damage induced by status epilepticus in the rat lithium-pilocarpine model.
Topics: Animals; Astrocytes; Autoradiography; Brain; Carbazoles; Carrier Proteins; Disease Models, Animal; E | 2017 |
Infarct volume and functional outcome after pre- and postoperative administration of metyrapone, a steroid synthesis inhibitor, in focal brain ischemia in the rat.
Topics: Animals; Behavior, Animal; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Glial Fibrillary Ac | 1999 |